A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Vascular inflammation is closely related to the pathogenesis of a diverse group of CVDs. Currently, it remains a great challenge to achieve site-specific delivery and controlled release of therapeutics at vascular inflammatory sites. Herein we hypothesize that active targeting nanoparticles (NPs) simultaneously responsive to low pH and high levels of reactive oxygen species (ROS) can serve as an effective nanoplatform for precision delivery of therapeutic cargoes to the sites of vascular inflammation, in view of acidosis and oxidative stress at inflamed sites. The pH/ROS dual-responsive NPs were constructed by combination of a pH-sensitive material (ACD) and an oxidation-responsive material (OCD) that can be facilely synthesized by chemical functionalization of β-cyclodextrin, a cyclic oligosaccharide. Simply by regulating the weight ratio of ACD and OCD, the pH/ROS responsive capacity can be easily modulated, affording NPs with varied hydrolysis profiles under inflammatory microenvironment. Using rapamycin (RAP) as a candidate drug, we first demonstrated in vitro therapeutic advantages of RAP-containing NPs with optimal dual-responsive capability, i.e. RAP/AOCD NP, and a non-responsive nanotherapy (RAP/PLGA NP) and two single-responsive nanotherapies (RAP/ACD NP and RAP/OCD NP) were used as controls. In an animal model of vascular inflammation in rats subjected to balloon injury in carotid arteries, AOCD NP could accumulate at the diseased site after intravenous (i.v.) injection. Consistently, i. v. treatment with RAP/AOCD NP more effectively inhibited neointimal hyperplasia in rats with induced arterial injuries, compared to RAP/PLGA NP, RAP/ACD NP, and RAP/OCD NP. By surface decoration of AOCD NP with a peptide (KLWVLPKGGGC) targeting type IV collagen (Col-IV), the obtained Col-IV targeting, dual-responsive nanocarrier TAOCD NP showed dramatically increased accumulation at injured carotid arteries. Furthermore, RAP/TAOCD NP exhibited significantly potentiated in vivo efficacy in comparison to the passive targeting nanotherapy RAP/AOCD NP. Importantly, in vitro cell culture experiments and in vivo animal studies in both mice and rats revealed good safety for AOCD NP and RAP/AOCD NP, even after long-term treatment via i. v. injection. Consequently, our results demonstrated that the newly developed Col-IV targeting, pH/ROS dual-responsive NPs may serve as an effective and safe nanovehicle for precision therapy of arterial restenosis and other vascular inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis
Seijkens, T. T. P., van Tiel, C. M., Kusters, P. J. H., Atzler, D., Soehnlein, O., Zarzycka, B., Aarts, S. A. B. M., Lameijer, M., Gijbels, M. J., Beckers, L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.055 · Cited by 195
A Targeting Nanotherapy for Abdominal Aortic Aneurysms
Cheng, J., Zhang, R., Li, C., Tao, H., Dou, Y., Wang, Y., Hu, H., & Zhang, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2188 · Cited by 109
Self-citationNosoudi, N., Nahar-Gohad, P., Sinha, A., Chowdhury, A., Gerard, P., Carsten, C. G., Gray, B. H., & Vyavahare, N. R. (2015) · Circulation Research · doi:10.1161/circresaha.115.307207 · Cited by 103
Cited by
Preparation and application of pH-responsive drug delivery systems
Ding, H., Tan, P., Fu, S., Tian, X., Zhang, H., Ma, X., Gu, Z., & Luo, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.056 · Cited by 645
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Lin, W., Hu, K., Li, C., Pu, W., Yan, X., Chen, H., Hu, H., Deng, H., & Zhang, J. (2022) · Advanced Materials · doi:10.1002/adma.202204455 · Cited by 33
Self-citationBi, J., Zhang, L., Zhang, P., Xu, S., Liu, Y., Zhang, X., Qiu, X., Bi, Y., Yan, F., Wei, H., et al. (2024) · Biomaterials Research · doi:10.34133/bmr.0075 · Cited by 12
Metadata
- Authors
- Zhang, R., Liu, R., Liu, C., Pan, L., Qi, Y., Cheng, J., Guo, J., Jia, Y., Ding, J., Zhang, J., & Hu, H.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 230
- Pages
- 119605
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2985424791
- Cited by
- 139
- References
- 10
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases. https://app.cochat.ai/papers/10.1016/j.biomaterials.2019.119605
- The paper
- Zhang, R., Liu, R., Liu, C., Pan, L., Qi, Y., Cheng, J., Guo, J., Jia, Y., Ding, J., Zhang, J., & Hu, H. (2020). A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases. Biomaterials. https://doi.org/10.1016/j.biomaterials.2019.119605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.